

### **Disclaimer**

- ▶ The views expressed by the presenters are not necessarily those of Ernst & Young LLP or other members of the global EY organization.
- ▶ These slides are for educational purposes only and are not intended to be relied upon as accounting, tax, or other professional advice. Please refer to your advisors for specific advice.

HCCA presentation- for presentation only not for distribution

### Speaker introductions





Lisa Alfieri, JD Senior Manager, Risk Transformation,

- Toda is a settor manger in the EY Advisory Services practice and EY's Health Lead for compliance practice and EY's Health Lead for compliance practices and EY's Health Lead for compliance practices and EY's Health Lead for compliance practices are compliance to the extra compliance to the extra compliance to the extra compliance management, for accounting, program management, data analytics, claims systems and risk management. He has wroted in public, commercial and academic markets. Toda is also engaged by senior management and audit committees to conduct compliance and risk and commercial and academic markets. Toda is also engaged by senior management and audit committees to conduct compliance and risk and commercial and academic markets. Toda is also engaged by senior management and audit committees to conduct compliance and risk and commercial and academic markets. Toda is also engaged by senior management and audit committees to conduct compliance and risk and the extra construction of the conduct compliance for the conduct compliance and risk and the conduct compliance and risk and the conduct compliance function integrations for the conduct compliance function integrations for professions and the senior acquisitions, claims processing implementation, the design, development and testing of operations reporting, operations results and professions. The conduct compliance and risk and professions are not immediately and professions are not immediately and professions. The conduct committees to conduct compliance and risk and professions are not immediately and professions. The conduct committees to conduct compliance and risk and professions are not immediately approached to the design, development and testing approached to the design, development and testing approached to the design, development and the design, development and the design, development and the design, development and migrations. The conduction of the design of the profession and professions are not instead to the design of the profession and ► Lisa is a senior manager in the EY Arbisory Services practice. Lisa's experiences include operational process improvement, risk management and mitigation, and major platform transformations for both commercial and government programs in the public and private sectors. Projects include but are not limited to providernetwork operational readeness, compliance function integrations from acquisitions, claims processing implementation, the design, development and testing of operations reporting, ICD-10 readiness, and 4010 to 5010 readiness.



EY


Agenda	
<ul> <li>▶ Objectives</li> <li>▶ Understanding MACRA (provider and payer)</li> <li>▶ Why MACRA is important for compliance officers</li> <li>▶ Who else is concerned</li> <li>▶ Getting ready</li> <li>▶ FAQs</li> </ul>	
Page 3 HCCA presentation-for presentation only not for distribution	
	1
Objectives and what participants will learn  Participants will learn:	
<ul> <li>An understanding of MACRA from both a provider and payer point of view</li> <li>Why it is important for compliance officers to understand MACRA</li> <li>What potential compliance considerations and impacts are involved as a result of providers looking to payers and health systems to support and collaborate to achieve MACRA objectives</li> <li>Considerations for the right infrastructure to support MACRA as payers put in processes to monitor their CMS universes</li> </ul>	
Page 4 HCCA presentation- for presentation only not for distribution	
MACRA is challenging health systems, forcing new discussions	
As the House and Senate look at the Affordable Care Act (ACA), we think that the Medicare Access and CHIP Reauthorization Act (MACRA) has the potential to be equally, if not far more, transformative to our health care system in terms of improving access to high-quality and lower-cost health care. However, MACRA has been a sleeper issue. Many industry stakeholders are still trying to understand its implications. The complexity of this daunting reimbursement system has all physicians – especially those in small-and medium-sized practices – deeply concerned about their future with Medicare patients. In fact, this push by CMS forces payers and providers to align values and outcomes that, up until now, have been so difficult to achieve in the commercially insured population alone.  MACRA is already shifting dialogues with health care leaders:  1. Will the government reduce payments with a new administration?  2. Are the criteria too restrictive?  3. Will the shared risk really improve care?  As it stands, MACRA will impact many Medicare stakeholders, not just providers, but also the nearly 50 million beneficiaries, the caregivers who serve them, the medical device manufacturers, the pharmaceutical companies and the health insurers.	
Page 5 HCCA presentation- for presentation only not for distribution	

### Conversion Acquisited fee Conversion For the sustainable growth rate (SGR) was enacted in 1997 by CMS to control Medicare spending by physicians; however, SGR did title to subdue cost and actually drove the growth in service volume and cost that plaques our health care system today. Quality of care and value is not implicitly included. MACRA is the first major change to the method of Medicare Part B physician payment in nearly two decades. It aims to rein in health care spending and redirect the health care dollar to better-quality care through the Quality Payment Program (QPP). RVUs (vork, PE, PLI) Payment modifier Physician quality reporting RVI makes ratios value with. Physician quality reporting Meaningful use Value-based payment modifier PL reses proteocode labelity mazaros. PL reses proteocode labelity mazaros. PL reses proteocoded labelity mazaros.

## What is the QPP? • The QPP involves the replacement of the traditional fee-for-service model for providers. MACRA repeals and replaces the SQR formula for determining Medicare payments for providers services by creating two models: the Merit-based incentive Payment System (MIPS) and Advanced Alternative Payment Models (APMs). Last year's performance data will impact reimbursement for 2019. What clinicians are affected by the QPP? • Physicians • Clinicial nurse specialist • Nurse practitioners • Combine replaces a patchwork system of Medicare reporting programs to: • Require higher levels of alignment from clinical professionals at the point of care because greater value is placed on quality measurement, coordination of care, population health and proper usage/management of resources • Combine existing quality reporting programs into one new system – physicians must be equally as good at meaningful use, clinical resource use via value-based modifiers (VBMs) and the Physician Quality Reporting System (PQRS) in their organization • la 2011, the scretzy of health and Human Services can broaden the eligible clinicians group to include others.


Why is the QPP a	big deal?						
	of investment needed (e.g., new performance reporting requirements, IT/data						
Risk of further	payment adjustments in 2019 and beyond						
<ul> <li>Greater value placed on coordination of care, population health and proper usage/management of resources</li> </ul>							
Need for clinicians to understand the impact that the QPP will have on their bottom line							
Vhy start QPP re	adiness now?						
	is will go into effect in 2019 through 2024 and beyond; however, 2017 data will be used 119 payment adjustments.						
MU, VBM, PQRS	QPP begins in 2019 and streamlines multiple Medicare quality programs (e.g., s) into two new payment paths. CMS will evaluate FY 2017 performance data to oursement in 2019.						
	Note: ~90% to 95% of clinicians will be part of MIPS.						


<ul> <li>The QPP is an actionable step toward achievin that delivers better care, smarter spending, and paying for value rather than just volume.</li> </ul>						
CMS's final rule recognized the importance of small, independent practices and the need to design a QPP that allows them to succeed.						
<ul> <li>93% of Medicare Part B charges will be subject to the incentive framework.</li> </ul>						
<ul> <li>The resource use category was (or will be) sim score for PY 2017.</li> </ul>	plified and weighted 0% of the final					
"Important: make sure you qualify."  Many organizations think they qualify by virtue of being an accountable care organization (ACO), but do not – validating qualification is imperative.	Goal of final rule:  *Make the transition to  MACRA as simple and flexible as possible.**					
	Andy Slavitt					
	Former Acting CMS Administrator					
Note:	modernhealthcare.com/article/20161014/NEWS/161019942.					



					commercial payers to value-based care (VBC			yer advanced APMs" ir
► B	Betwe	en 2017 thr	ough 2019, provid	ders will loo	k to payers and health s	stems to s	upport and collabo	
MACRA's objectives. During this time, many providers will assess which payers are best to partner with for advanced APMs.								
<ul> <li>Payers can offer clinical decision-support tools, access to data, better integrated care teams and addition</li> </ul>								
		es and share et position.	knowledge from p	ast experie	nce predicting risk to sh	ow value-ad	dd services and ma	aintain/grow
- "	ilaike	t position.						
	Paver education to their Condi			Conduct	a MACRA readiness	Create i	ntegrated	
		provider net	work on	and VB	and VBC capability assessment		VBC/MACRA road	
MACRA/VBC and conduct market assessment to		with providers to identify key gaps for providing VBC		map with participating provider entities and				
	determine provider network maturity (data testing)			secure ci		apital funding		
	1		-	3		5	$\overline{G}$	Operational quality data model to look at
		2		4	1	6		VBC
	Outline MACRA/VBC			Work with providers to		Conduct operation		
		strategy and analyze potential     participating providers for			identify and define essential readiness competencies necessary for		readiness activi	ties
	VBC arrangements				an APM (risk-bearing entity)			
								N

## Value-based care contracting models Approaches for health systems and payers Conservative approach Conduct a value-based payment readiness assessment and quentitative metrics used to evaluate performance or provider network adequacy Assess and cruste an improvement plan for provider network adequacy and impact on behavior Moderate/Aggressive approach Conduct a gap analysis and comparative analysis between health expensive analysis patient or set assess and cruste an improvement plan for provider network adequacy and impact on behavior Assess and rousel an improvement plan for provider network adequacy Conduct a sussessment of current qualitative and unafficial venture aperson of compensation is confingent on the provider of the pro





Payer and provider cooperation	Payer	and	provider	coop	eration
--------------------------------	-------	-----	----------	------	---------

Compliance officer considerations

Various measurement criteria are similar for health plans and providers, especially in regards to the clinical quality metrics.

especially in regards to the clinical quality metrics.

As health plans review their provider contracts, they can review provider performance and facilitate data sharing with each other as part of a value-based care contract.

- ➤ This will drive hospital quality risk departments to be more attuned to case management reviews, denials, etc. This can drive improved infrastructure to include compliance dashbaards for analytics and workflow.
- include compliance dashboards for analytics and workflow.

  ► Smaller provider groups or independent providers may not have a capital budget or bandwidth in their risk management teams to allow for enhancements of their EHRs. However, payers can leverage what providers send in data (unstructured and structured) to help providers meet MACRA requirements.
- Per MACRA, health plans should also be able to help providers educate their patients on the costs of care and the treatment options. In summary, the drive for collaboration between payers and providers will be critical. Compliance can help support monitoring.

Page 15

HCCA presentation- for presentation only not for distribution



### Potential impacts of risk sharing

Compliance officer considerations

- MACRA is about managing risk, which is where compliance and quality work closely together to help look at patient populations and manage financial risk through the reimbursement process.
- 2. Health plans are preparing to see how they can be able to support providers on their network. Potential risks of provider data:
  - ► Completeness missing key information
  - Accuracy reporting from EHR systems could be inaccurate if not tested periodically
  - Quality able to get data from the key systems
- 3. Payer risks can be mitigated through defined data protocols validated periodically similar to CMS universe protocols data validation.

Page 1

HCCA presentation- for presentation only not for distribution



### Other key risks and potential mitigating activities

Compliance officer considerations

Function APM req.		Risks/issues		
IT	Data integration and sophisticated analytics capabilities	Data sharing and access –     EHRs/HIEs     Data integrity     Insufficient data warehouse and analytics platforms or modeling tools		
Ops	Integrated clinical operations aligned with consistent incentives	End-to-end patient experience and services     Disparate financial and clinical operations and decision-making     Increased marketing scrutiny     UM/RM shifted to providers		
Finance	Sophisticated budgeting, planning and forecasting; understanding risk contracting	Cannibalization of revenue     Reduce costs without hurting quality     Cost/acrual accounting     Ability to pay losses     Dividing shared savings/losses and incentive payments     Hospitals, specialists, PGPs     Funding up-front sunk costs		

	Potential mitigation									
	٠	Data management plan								
	۰	Data quality assessment and data quality management plan								
	۰	Data warehouse investment								
	٠	Integration of payer, provider data								
	٨	Patient flow diagrams and redesign for end-to-end patient care exp.								
١	۰	Marketing compliance plan								
1	۰	Organizational redesign; task forces								
1	۰	Integrate financial and clinical decision- making functions								
	۰	Request to CMS to withhold savings								
	۰	Analytics platform and modeling								


Page 17


HCCA presentation- for presentation only not for distribution



Othe Comp	r key ris	sks and potential fficer considerations	mitigating a	ctivities
Function Clinical	APM req. Physician	Risks/issues  Physician autonomy	Potential mitigati	on e care contracts for
Cillical	alignment on care	Size and cost of formulary     Decentralized supply chain	high-cost patie	
	management and measurement	Patient preference     High-risk patients	► Product portfol sales access	io managers; restricting
People	Staff alignment	➤ Medical staff buy-in and contracting	➤ Supply chain n  Change manage	
	on care management and	<ul> <li>Control over physician and staff (alignment)</li> </ul>	➤ Physician char ➤ Build physician	performance metrics
	measurement	<ul> <li>Measurement of individual vs. grouperformance and costs</li> <li>Variations in practice/treatment</li> </ul>	into annual cor	itracts
Patients	Ability to track patient across	Size of patient population     Patient satisfaction	➤ Track/measure	patient loyalty and
	full continuum of care	Patient satisfaction     Patient attribution	▶ Formalize patie	ent attribution method ljustments in contracts
		Consumer health engagement	► Recruit more p	
Page 18		HCCA presentation- for presentation or	nly not for distribution	EY
Who	ا معام ا	s concerned?		
Accol	untable c	are organizations (A	(COs)	
		. 5 (7.	/	
				ly concerned about
			the direction the Co	
			but also with the co	onflicts created by
			its other value-bas programs such as	bundled payment,
			and when you add costs to run an AC	that to how much it
			significant number	of ACOs ready to
			leave the [Medicar Program, MSSP] p	rogram."
a				
Clif Gau	s, President a	and CEO of NAACOS, said in a	a public statement.	
Page 19		HCCA presentation- for presentation or	nly not for distribution	EY
Why	are A	COs concerned	l?	
Needin	ng to help s	serve their community, a	nd there is a sho	rtage
		in the Medicare Shared Savir	ngs Program (MSSP)	will be allowed to:
	rticipate in an a stain 5% payme			
3. Oth	her providers ca	an participate in bundled payment i		
servic	ce agencies.	Os will need to show their coor All focused to improve populati	ion health manageme	ent. Examples
inclu	de employing	community health programs to nation and patient education.		
▶ The r	risk¹:			
ava	ailable to meet	upport community health systems, behavioral health needs of their pa		
ma	nagement will	be key. s see funding as a barrier to conne		
		eel they are in a catch-22.	g area providers with	5101 001 1100
Note:				
1 Based or	n findings from the	e Robert Wood Johnson Foundation and	Premier Research Institute	
Page 20		HCCA presentation- for presentation or	nly not for distribution	EY
J		,		ET

# Payer and provider infrastructure: Referring back to the article in the HFMA, payers and providers entering and renegotiating value-based contracts will likely need robust infrastructure and dashboards to track the three Ps (patient, procedures, performance). This will relate to the following: 1. Patient treatments 2. Patient treatments 3. Provider follow-up and medical/treatment adherence Life sciences and path to influence care and cost or care: To support improved patient experiences, care and cost management, life sciences companions should consider focusing on the outcomes most important to the patient, from interactions with the pharmacy, to medical devices. Research and clinical trial organizations: Academic, private and commercial institutions should work closely with their stakeholders to determine a definition of value that they can attribute to the drug therapy or device. Example: Speed to trial on less-invasive treatments and protocols





Conclusions on getting ready for MACRA	
<ul> <li>For non-provider groups, establish a MACRA steering committee</li> <li>Conduct a risk assessment of the current process to capture information to support your MACRA decisions</li> <li>Actively involve stakeholders within your organization so that the considered processes and systems addressing MACRA are compliant</li> <li>Align to the risk management process required for MACRA</li> <li>Document and keep decision-making rationale for changing processes with providers</li> <li>Just because you are not a provider does not mean that MACRA can not impact you</li> </ul>	
Page 24 HCCA presentation-for presentation only not for distribution	
In closing	7
In closing	
<ul> <li>Gained an understanding of MACRA from both a provider and payer point of view</li> <li>Why it is important for compliance officers to understand MACRA</li> <li>What potential compliance considerations and are involved as a result of providers looking to payers and health systems to support and collaborate to achieve MACRA objectives</li> <li>Considerations for the right infrastructure to support MACRA as payers put in processes to monitor their CMS universes</li> </ul>	
Page 25 HCCA presentation-for presentation only not for distribution	
Questions and answers	
► Q&A	
<ul> <li>Contacts:         <ul> <li>Todd Gower, todd.qower@ev.com</li> <li>Lisa Alfieri, JD, lisa alfieri@ev.com</li> </ul> </li> <li>Send us an email with your questions and comments</li> </ul>	

Thanks for your participation			
A.	-		
WENT -	3		
Table 1	-		
and the			
Page 27 HCCA presentation- for presentation only not for distribution	on <b>EY</b>		
EY   Assurance   Tax   Transactions   Advisory			
About ET // ET all poble leader in assurance, its "transaction and advancy services." The register and quality services we obtain the joud transact and confidence in the recognition and used to confidence in the recognition about services would promise to add confidence in the recognition and the recognition and the recognition and promises to all of our statements into all ones, then of the recognition and the recognition			
E' refers to the global organization, and my refer to see or one, of the number fermost effect. A foung clitical Limited, each of which is a separate legal erity. Error & Young Clobal Limited, a Ut Company inflinite by guarantee, does not provide services to clients. For more information about our organization, prosess with y your.			
Ernst & Young LLP is a client-serving member firm of Ernst & Young Global Limited operating in the US.		-	

© 2018 Ernst & Young LLP. All Rights Reserved.